Neurodegenerative disease biotechnology company: Xinxu Biotechnology APRINOIA Therapeutics Inc. (APRI)

Established in 2015, Xinxu Biotechnology APRINOIA Therapeutics Inc. (NASDAQ: APRI), headquartered in Cambridge, Massachusetts, USA, has 72 full-time employees and is a clinical Biotechnology Company We are committed to protecting the brain health of patients and changing the clinical results of a wide range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapies.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

Xinxu Biotechnology APRINOIA Therapeutics Inc. (APRI)

Xinxu Biotechnology is a biotechnology company with deep research foundation. It is committed to providing the best diagnostic tools and novel therapies in the same category, improving the treatment results of various neurodegenerative diseases, and protecting the brain health of patients. The English name "APRINOIA" of Xinxu Biotechnology is a combination of "apricum", which symbolizes sunshine in Latin, and "noia", which means "mind" in Greek. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

Xinxu Biotechnology cooperates with well-known organizations and professional research institutions in the field of neuromedicine, introduces precision medicine into neuroscience, and actively breaks through the boundaries of neurodegenerative disease diagnosis and treatment. Xinxu Biotechnology will continue to expand the company's partnership through late clinical research and commercialization. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

APRINOIA and Biogen and Celgene (by Bristol Myers Squibb Acquisition) and other leading biotechnology companies in the world to develop new therapies and precise diagnosis for the treatment of neurodegenerative diseases, including certain non exclusive license agreements for its leading tau PET tracer APN-1607. APRINOIA announced that it would authorize the Chinese rights of APN-1607 to a large pharmaceutical company, thereby realizing the commercialization of APN-1607 in China in 2024. The licensee has committed to pay about US $8 million and RMB 14 million as advance payment, and has committed to pay milestone payments and royalties up to 15% of China's sales. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

APRINOIA will continue to lead the development of APN-1607 in other jurisdictions. APN-1607 is conducting the second phase test of AD in the United States, Japan, etc., and is preparing to conduct the third phase test of PSP in the United States, subject to the regulatory approval of FDA. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

APRINOIA has established four platforms with different modes: unique PET diagnostic tracer, small molecule regulator, antibody and degradation agent. Each model targets pathological aggregation proteins, such as tau, α - synuclein and TDP43, which contribute to the pathogenesis of rare dementia or dyskinesia, including PSP, multisystem atrophy (MSA) and frontotemporal dementia (FTD), as well as common diseases, such as AD and Parkinson's disease (PD). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

Xinxu Biotechnology focuses on two types of neurodegenerative diseases caused by pathological proteins, namely tau proteinopathy (including Alzheimer's disease and progressive supranuclear paralysis (PSP)) and α - synucleoprotein disease (including Parkinson's disease and Lewy body dementia (LBD)). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

Tau proteinosis Tau proteinopathy is mainly a neurodegenerative disease caused by accumulated tau protein. Tau protein has natural normal form and toxic form. In addition, the toxic tau protein will further "infect" adjacent healthy cells. Toxic tau protein can be transmitted among neurons and spread to different brain regions, resulting in progressive brain degeneration. According to the severity of tau protein lesions, in the late stage of disease development, patients usually have cognitive and behavioral defects, accompanied by motor disorders. The main tau protein diseases include Alzheimer's disease (AD), progressive supranuclear paralysis (PSP) and frontotemporal dementia (FTD). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

Alpha synucleopathy α - Synucleopathy is a neurodegenerative disease caused by the accumulation of abnormal α - Syn in neurons and glia to form insoluble fibers. In terms of pathogenesis, these diseases are usually accompanied by α Syn metabolic disorder, causing high α Syn levels and α Syn accumulation. The types of α Syn abnormalities may be related to multiple systemic degeneration, causing a wide range of clinical syndromes, including dementia and dyskinesia. The major α - synuclein diseases include Parkinson's disease (PD), Lewy body dementia (LBD) and multisystem atrophy (MSA). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

For the 12 months ended June 30, 2023, the revenue of Xinxu Biotechnology was $9 million. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/apri.html

Xinxu Biotechnology APRINOIA Therapeutics Inc. (APRI) is listed

On January 18, 2023, APRINOIA Therapeutics Inc. and the Special purpose acquisition company Ross Acquisition Corp II（ New York stock exchange Code: ROSS, ROSS. U, ROSS WS) announced today that they have reached a final agreement for business combination.

ROSS has signed a business merger agreement with APRINOIA. According to the agreement, APRINOIA and ROSS will respectively become wholly-owned subsidiaries of the newly established entity APRINOIA Therapeutics Holdings Limited after the merger. Business combination The valuation of the combined business after the transaction is completed is up to $319.6 million.

As part of the business merger, all existing shareholders of APRINOIA will transfer 100% of their shares in APRINOIA to the new company. APRINOIA's existing shareholders are expected to hold 42% to 74% of the shares of the new company, depending on the redemption level of ROSS shareholders. The board of directors of ROSS and APRINOIA unanimously approved the proposed business merger, which is expected to be completed in the first half of this year.

On August 21, 2023, Ross Acquisition Corp II (ROSS) announced this afternoon that it had terminated its merger with APRINOIA, a drug developer, with immediate effect. The two sides did not disclose the reasons for the decision to cancel the transaction, nor did they provide more details.

APRINOIA Therapeutics Inc. US equity investment

APRINOIA Therapeutics submitted to the SEC on January 26, 2024 IPO It is proposed to raise up to US $50 million through IPO. Xinxu Biotechnology plans to be listed on NASDAQ with the stock code of APRI. Tiger Brokers （ Tiger Securities ）Is the sole bookrunner of the transaction. Pricing terms are not disclosed.

On February 26, 2024, APRINOIA Therapeutics announced that it planned to issue 2 million shares at a price of US $10-14 to raise US $24 million. At the midpoint of the proposed scope, the fully diluted market value of APRINOIA Therapeutics will reach $373 million.